Gensight Biologics SA
PAR:SIGHT
US |
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
|
US |
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
|
US |
Bank of America Corp
NYSE:BAC
|
Banking
|
|
US |
Mastercard Inc
NYSE:MA
|
Technology
|
|
US |
Abbvie Inc
NYSE:ABBV
|
Biotechnology
|
|
US |
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
|
US |
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
|
US |
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
|
US |
Visa Inc
NYSE:V
|
Technology
|
|
CN |
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
|
US |
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
|
US |
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
|
US |
Coca-Cola Co
NYSE:KO
|
Beverages
|
|
US |
Realty Income Corp
NYSE:O
|
Real Estate
|
|
US |
Walt Disney Co
NYSE:DIS
|
Media
|
|
US |
PayPal Holdings Inc
NASDAQ:PYPL
|
Technology
|
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
52 Week Range |
0.29
0.704
|
Price Target |
|
We'll email you a reminder when the closing price reaches EUR.
Choose the stock you wish to monitor with a price alert.
Johnson & Johnson
NYSE:JNJ
|
US | |
Berkshire Hathaway Inc
NYSE:BRK.A
|
US | |
Bank of America Corp
NYSE:BAC
|
US | |
Mastercard Inc
NYSE:MA
|
US | |
Abbvie Inc
NYSE:ABBV
|
US | |
Pfizer Inc
NYSE:PFE
|
US | |
Palantir Technologies Inc
NYSE:PLTR
|
US | |
Nike Inc
NYSE:NKE
|
US | |
Visa Inc
NYSE:V
|
US | |
Alibaba Group Holding Ltd
NYSE:BABA
|
CN | |
3M Co
NYSE:MMM
|
US | |
JPMorgan Chase & Co
NYSE:JPM
|
US | |
Coca-Cola Co
NYSE:KO
|
US | |
Realty Income Corp
NYSE:O
|
US | |
Walt Disney Co
NYSE:DIS
|
US | |
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
This alert will be permanently deleted.
Intrinsic Value
The intrinsic value of one SIGHT stock under the Base Case scenario is 0.431 EUR. Compared to the current market price of 0.395 EUR, Gensight Biologics SA is Undervalued by 8%.
The Intrinsic Value is calculated as the average of DCF and Relative values:
Valuation Backtest
Gensight Biologics SA
Run backtest to discover the historical profit from buying and selling SIGHT based on its intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Price Target |
Loading
|
Revenue Forecast |
|
Operating Income Forecast |
|
Earnings Forecast |
|
Select up to 3 indicators:
Select up to 3 indicators:
Months
Months
Months
Months
Select up to 2 periods:
Revenue & Expenses Breakdown
Gensight Biologics SA
Balance Sheet Decomposition
Gensight Biologics SA
Current Assets | 6.5m |
Cash & Short-Term Investments | 2.1m |
Receivables | 2.4m |
Other Current Assets | 2m |
Non-Current Assets | 2.6m |
Long-Term Investments | 502k |
PP&E | 2m |
Intangibles | 75k |
Other Non-Current Assets | 1k |
Current Liabilities | 25.3m |
Accounts Payable | 5.6m |
Accrued Liabilities | 1.8m |
Other Current Liabilities | 17.8m |
Non-Current Liabilities | 14.5m |
Long-Term Debt | 6.2m |
Other Non-Current Liabilities | 8.4m |
Earnings Waterfall
Gensight Biologics SA
Revenue
|
1.3m
EUR
|
Operating Expenses
|
-31m
EUR
|
Operating Income
|
-29.7m
EUR
|
Other Expenses
|
3.5m
EUR
|
Net Income
|
-26.2m
EUR
|
Free Cash Flow Analysis
Gensight Biologics SA
EUR | |
Free Cash Flow | EUR |
SIGHT Profitability Score
Profitability Due Diligence
Gensight Biologics SA's profitability score is 22/100. The higher the profitability score, the more profitable the company is.
Score
Gensight Biologics SA's profitability score is 22/100. The higher the profitability score, the more profitable the company is.
SIGHT Solvency Score
Solvency Due Diligence
Gensight Biologics SA's solvency score is 22/100. The higher the solvency score, the more solvent the company is.
Score
Gensight Biologics SA's solvency score is 22/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
SIGHT Price Targets Summary
Gensight Biologics SA
According to Wall Street analysts, the average 1-year price target for SIGHT is 0.388 EUR with a low forecast of 0.364 EUR and a high forecast of 0.42 EUR.
Shareholder Yield
Current shareholder yield for SIGHT is .
Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?
SIGHT Price
Gensight Biologics SA
Average Annual Return | 61.82% |
Standard Deviation of Annual Returns | 106.02% |
Max Drawdown | -97% |
Market Capitalization | 40.9m EUR |
Shares Outstanding | 103 457 652 |
Percentage of Shares Shorted |
N/A
|
Profile
Country
Industry
Market Cap
Dividend Yield
Description
GenSight Biologics SA is a clinical-stage gene therapy company. The company is headquartered in Paris, Ile-De-France. The company went IPO on 2016-07-13. The firm develops and commercializes gene therapy-based treatments of retinal degenerative diseases. The company develops approaches to prevent retinal degeneration in selected pathological conditions and to restore vision in patients suffering from low vision or blindness. The firm intends notably to develop a gene replacement therapy for Leber's hereditary optic neuropathy (LHON) and an optogenetic therapy for retinitis pigmentosa (RP).
Contact
IPO
Employees
Officers
The intrinsic value of one SIGHT stock under the Base Case scenario is 0.431 EUR.
Compared to the current market price of 0.395 EUR, Gensight Biologics SA is Undervalued by 8%.